Charles ODonnell
Vice President, Head of Computational Genomics and Data Sciences at Omega Therapeutics - Cambridge, MA, US
Charles ODonnell's Colleagues at Omega Therapeutics
Yael Katan-Khaykovich
Senior Scientist, Process and Analytical Sciences
Kelcie Tierney
Strategic Assistant to the CEO and Manager, Corporate Communications
Charles ODonnell's Contact Details
617-949-4360
Greater Boston Area
Omega Therapeutics
Charles ODonnell's Company Details
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.